BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Inside Plan with Houseplants: An Aide- Pedal Power: Divulging Well known Bike Brands for Each Cyclist
- The most effective method to Integrate Compact disc Rates into Your Retirement Arranging
- Step by step instructions to Lessen Your Gamble of Creating Cellular breakdown in the lungs
- African nations push to recognize crimes of colonialism in Algeria
- My Excursion to Monetary Autonomy: Awesome ways to save cash
- Vote In favor of Your Favored Comupter Game
- Misinterpretations and Mistakes Portrayed by Hollywood in the General set of laws
- Wisconsin archaeologists identify 16 ancient canoes in a prehistoric lake 'parking lot'
